Clinical trial NCT05300048: Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations
Official title: A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) and with or Without Nab-paclitaxel in Adult Subjects with Advanced Solid Tumors with PIK3CA Mutations with or Without PTEN Loss
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumor
PIK3CA Mutation
PTEN Loss of Function Mutation
Keywords: PIK3CA Mutation
PTEN Loss of Function Mutation
Lead sponsor: Faeth Therapeutics
Sponsor class: INDUSTRY
First posted: 2022-03-29
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

Detailed description: Targeted anticancer drugs have side effects that often result in a poor quality of life, noncompliance, dose decreases, or discontinuation, all of which can affect efficacy. This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib when combined with an insulin suppressing diet and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

Eligibility criteria: Inclusion Criteria:

1. Able to provide written informed consent.
2. Age ≥18 at Visit -1 (screening).
3. Histologically or cytologically confirmed recurrent solid tumors.

   1. Cohort 1a: any extracranial solid tumor (may include EC, ovarian clear cell, or ovarian endometrioid carcinoma if subject is not eligible for nab-paclitaxel in Cohort

      1b)
   2. Cohort 1b: either recurrent or persistent endometrial adenocarcinoma (EC) with the following histologic epithelial cell types: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and carcinosarcoma or; ovarian cancer (OC) with the primary tumor having ≥ 50% clear cell histomorphology or ovarian clear cell or ovarian endometrioid carcinoma.
   3. Cohort 2: adenocarcinoma of the colon or rectum.
   4. Cohort 3: recurrent or persistent endometrial adenocarcinoma with the following histologic epithelial cell types as described for Cohort 1b
   5. Cohort 4: OC primary tumor carcinomas as described for Cohort 1b
4. Tumor must harbor an activating mutation in the PIK3CA gene with or without PTEN loss, either previously documented or determined during screening.
5. Fresh or archival tumor biopsy with sufficient material to be sent to the designated laboratory for PD analyses. For subjects who consent to future research, an additional 5 slides from a surgical specimen or biopsy is required.
6. Cohort 1a - Dose Modification (subjects with any solid tumor): failed, were intolerant of, or ineligible for no more than three prior lines of therapy (LOT) for advanced/metastatic disease or refused SOC therapy.
7. For all cohorts, in the unlikely scenario that a subject refused all available SOC they may proceed with trial. These subjects would be regarded as having 0 prior LOT.
8. Cohorts 1b, 2, 3, and 4 - failed, were intolerant of, ineligible for, or have refused SOC therapy for advanced/metastatic disease (AJCC stage III and IV) and:

   1. Cohort 2 (subjects with colorectal cancer): Have failed no more than two prior LOT for metastatic CRC.
   2. Cohort 1b, and Cohort 3 (subjects with EC): Have no more than three prior chemotherapeutic regimens for management of endometrial carcinoma (neo-adjuvant and/or adjuvant chemotherapy will be counted as one prior LOT). Prior hormonal therapy will not count as a systemic regimen.
   3. Cohort 1b, and Cohort 4 (subjects with clear cell or endometrioid OC): Subjects must have had no more than three prior chemotherapeutic regimens for management of ovarian carcinoma. Prior hormonal therapy will not count as a systemic regimen.
9. Life expectancy of at least 3 months.
10. At least one measurable lesion (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1).
11. ECOG PS of 0 to 1.
12. Adequate organ function

    1. Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L or ≥1.5 x 10\^9/L if planned to be treated with nab-paclitaxel, platelet count ≥75 × 10\^9/L, and hemoglobin ≥8.5 gm/dL (may be transfused to reach this hemoglobin level unless due to blood loss).
    2. Liver transaminases (AST and ALT) ≤2.5 × upper limit of normal (ULN) (\<5 × ULN if liver metastases are present), and total bilirubin ≤1.5 × ULN (\<3 x ULN if subject has Gilbert Syndrome).
    3. INR ≤1.5 x ULN unless subject is on anticoagulants that would affect the INR, then INR must be in the desired therapeutic range as judged by the Investigator.
    4. Albumin level ≥3.0 mg/dL or ≥ the lower limit of normal.
    5. Renal: Serum creatinine ≤2 x ULN
13. Ability to take PO medication, be willing to adhere to study procedures and Study Intervention administration, and receive, consume, and comply with Study ISD.
14. For women of child-bearing potential, a negative serum pregnancy test collected at screening (Visit-1) and negative urine pregnancy test collected at baseline (Visit-1) and use of physician-approved method of birth control from the time of the pregnancy test performed at screening to 90 days following the last administration of Study Drug or, if applicable, 6 months following the last administration of nab-paclitaxel.
15. Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last administration of Study Drug.

Exclusion Criteria:

1. Diagnosis of primary malignant brain tumor.
2. Has had serabelisib, alpelisib, or other PI3K inhibitor.
3. Leptomeningeal disease and symptomatic or untreated brain metastases.
4. Diagnosis of, or requiring treatment for, another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 90 days prior to the first dose of Study Drug).
5. Is less than 21 days from therapeutic radiation or chemotherapy prior to the first day of dosing with Study Drug and has not recovered to Grade ≤ 1 from all clinically significant toxicities related to prior therapies.
6. For subjects receiving nitrosoureas or mitomycin C, the subject is \< 6 weeks from last dose. For monoclonal antibody therapy, the subject is \< 1 half-life or \<4 weeks from the last dose.
7. Chronic, systemically administered glucocorticoids in doses equivalent to \>5 mg prednisone daily. Replacement corticosteroids for adrenal insufficiency are permitted.
8. Diabetes mellitus requiring insulin or insulin secretagogue therapy.
9. Poorly controlled diabetes mellitus defined as glycosylated hemoglobin A1c (HbA1c) \>7.5% or fasting blood sugar \>160 mg/ dL.
10. Known impaired cardiac function or clinically significant cardiac disease.
11. QTcF interval \>470 msec found at screening.
12. Myocardial infarction, cardiac stent placement, or unstable angina within 6 months before the first administration of Study Drug.
13. Have clinically significant peripheral vascular disease.
14. Manifestations of malabsorption
15. Other clinically significant comorbidities.
16. Pregnant (positive serum pregnancy test), planning to become pregnant during the study, or breastfeeding/planning to breastfeed during the study.
17. Have taken strong CYP3A4 inducers/inhibitors within 7 days before the first administration of serabelisib or have conditions that require the concomitant use of CYP3A4 inducers/inhibitors.
18. Untreated or poorly controlled, gastro-esophageal reflux disease.
19. Have taken histamine-H2 receptor antagonists within 12 hours before the first administration of serabelisib.
20. Have taken PPI within 7 days or 5 half-lives (whichever is the shorter duration) before the first administration of serabelisib or are anticipated to need PPI during the study.
21. Have taken neutralizing antacids within 4 hours before the first administration of serabelisib or are anticipated to need frequent antacid use during the study.
22. Subjects with poorly controlled human immunodeficiency virus, hepatitis B virus, and/or hepatitis C virus infections.
23. Known allergies to nab-paclitaxel or excipients, serabelisib or excipients or the ISD
24. Severe, uncontrolled gout.
25. A BMI \<18.5 kg/m2, or serious or refractive cachexia or anorexia that, in the Investigator's opinion, realistically prohibits subjects from having energy or appetite sufficient to reliably engage in a strict ISD regimen for an extended time.
26. Any condition that renders the subject unable to satisfactorily chew, swallow, digest, or tolerate (i.e., persistent diarrhea) the majority of foods and liquids of the Study ISD.
27. History of severe nephrolithiasis requiring urologic intervention.
28. Participation in a diet or weight loss plan within 10 days prior to the first administration of Study Drug.
29. Severe constipation or condition where exacerbation of constipation is not advisable (eg, small bowel obstruction history).
30. History of anaphylaxis from food allergy or other disease state requiring avoidance of a particular food, such as celiac disease.
31. Diagnosed eating disorder in the past 10 years.
32. Unwilling to take a non-vegan or non-vegetarian diet.
33. Peripheral neuropathy ≥ CTC Grade 2

Primary outcomes:
measure: Cohorts 1a/1b: Evaluate safety
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Evaluate compliance
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.
timeFrame: Through study completion, an average of 8 months.
Secondary outcomes:
measure: Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring ORR.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring PFS.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring OS.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DoR.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b: Antitumor efficacy of study intervention by measuring DCR.
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Confirm safety
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Confirm the compliance of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring PFS).
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring OS).
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DoR).
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Additional assessments of antitumor efficacy of study intervention (Measuring DCR).
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohort 2, 3, 4: Assess the population PK and intra-tumoral concentration of study intervention.
timeFrame: Through study completion, up to 12 months.
Other outcomes:
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of PD of study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of immune markers in response to study intervention.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of efficacy.
timeFrame: Through study completion, up to 12 months.
measure: Cohorts 1a/1b, 2, 3, 4: Assessment of genetic predictors of toxicity.
timeFrame: Through study completion, up to 12 months.
Locations:
city: Birmingham
country: United States
facility: University of Alabama
state: Alabama
city: Anaheim
country: United States
facility: Pacific Cancer Specialists
state: California
city: Los Angeles
country: United States
facility: Valkyrie Clinical Trials
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Presbyterian
state: California
city: Indianapolis
country: United States
facility: Community Health Network, Inc.
state: Indiana
city: Rochester
country: United States
facility: Mayo Clinic - Rochester
state: Minnesota
city: Belleville
country: United States
facility: New Jersey Cancer Care, PA
state: New Jersey
city: Englewood
country: United States
facility: Englewood Health
state: New Jersey
city: Lake Success
country: United States
facility: Northwell Health
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Greenville
country: United States
facility: East Carolina University
state: North Carolina
city: Philadelphia
country: United States
facility: University of Pennsylvania Health System, Perelman Center for Advanced Medicine
state: Pennsylvania
city: Sioux Falls
country: United States
facility: Avera Cancer Institute
state: South Dakota
city: Beaumont
country: United States
facility: Baptist Hospitals of Southeast Texas
state: Texas
city: Houston
country: United States
facility: Oncology Consultants, PA
state: Texas
city: Kingwood
country: United States
facility: Lumi Research
state: Texas
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Vicky Makker
role: PRINCIPAL_INVESTIGATOR
References: